Audit 348413

FY End
2023-12-31
Total Expended
$1.09M
Findings
0
Programs
3
Organization: Cytocybernetics, Inc. (NY)
Year: 2023 Accepted: 2025-03-26

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $851,325 Yes 0
47.041 Engineering $164,676 Yes 0
93.242 Mental Health Research Grants $72,306 Yes 0

Contacts

Name Title Type
G69NH6PMLT75 Dr. Randall L. Rasmusson Auditee
7163801313 Sarah Hopkins Auditor
No contacts on file

Notes to SEFA

Title: 1. Summary of Significant Accounting Policies Accounting Policies: Basis of Presentation The accompanying Schedule of Expenditures of Federal Awards (SEFA) presents the activity of the federal award programs administered by the Cytocybernetics, Inc. (the Entity), which is aware and has been informed that such funds require separate audit procedures. Federal awards received directly from federal agencies are included on the SEFA. Basis of Accounting The Entity uses the income tax basis of accounting for the Program. Indirect Costs The Entity does not use the de minimis indirect cost rate permitted by the Uniform Guidance. Rather, the Entity applies an indirect rate as permitted per grant agreements. De Minimis Rate Used: N Rate Explanation: Indirect Costs The Entity does not use the de minimis indirect cost rate permitted by the Uniform Guidance. Rather, the Entity applies an indirect rate as permitted per grant agreements. Basis of Presentation The accompanying Schedule of Expenditures of Federal Awards (SEFA) presents the activity of the federal award programs administered by the Cytocybernetics, Inc. (the Entity), which is aware and has been informed that such funds require separate audit procedures. Federal awards received directly from federal agencies are included on the SEFA. Basis of Accounting The Entity uses the income tax basis of accounting for the Program. Indirect Costs The Entity does not use the de minimis indirect cost rate permitted by the Uniform Guidance. Rather, the Entity applies an indirect rate as permitted per grant agreements.